Volume 95 Issue 20 | p. 19 | Concentrates
Issue Date: May 15, 2017

Sanofi to keep Cepia contract business

Department: Business
Keywords: outsourcing, Sanofi, Cepia_sell, contract manufacturer

The French drugmaker Sanofi says it has decided not to divest Cepia, its contract manufacturing arm. The business produces active pharmaceutical ingredients at 16 Sanofi chemical and biotech sites. It also offers process development services. In the biotech field alone, the business counts more than 280 customers in 62 countries. The decision to keep Cepia is based on its financial improvement and promising prospects, Sanofi says.

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society